Skip to main content
Premium Trial:

Request an Annual Quote

MorphoSys' AbD Serotec Unit to Provide Research Antibodies for Proteomika

NEW YORK (GenomeWeb News) — MorphoSys said today that Proteomika, a proteomics biomarker-discovery subsidiary of Progenika Biopharma, has ordered “multiple” research antibodies from its AbD Serotec business unit.
 
The agreement places Proteomika “among the largest customers for custom monoclonals services provided by AbD Serotec,” MorphoSys said, but did not disclose financial details.
Under the terms of the agreement, AbD Serotech will provide Proteomika with HuCal-based research antibodies against “a broad range of target molecules.”
 
Proteomika is involved in cancer-related in-house discovery projects at the bioGUNERResearch Institute, and has established research collaborations for non-invasive diagnostics, pharmacoproteomics markers, and novel therapeutic targets.